- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Ibrutinib (cll/sll) – November 2017
Ibrutinib (CLL/SLL): Capsule 140 mg ; Imbruvica®
Last updated
16 March 2018